Beta-lactams are a group of drugs considered to be the treatment of choice in cases of salmonellosis, although many isolates that are clinically resistant to these compounds have been reported. We developed an in vitro model to determine the dynamics of the generation of resistant mutants following repeated exposure to these drugs. All the isolates exposed repeatedly to amoxicillin and cefotaxime exhibit a decrease in their susceptibility to these compounds and to many other beta-lactam drugs. However, in many cases this reduction in susceptibility is not detected if the CLSI criteria are applied. These mutants with reduced susceptibility may be the reason for therapeutic failures, so this phenomenon should be studied in greater detail by means of in vitro models or clinical studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10156-005-0430-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brief monocular deprivation during a developmental critical period, but not thereafter, alters the receptive field properties (tuning) of neurons in visual cortex, but the characteristics of neural circuitry that permit this experience-dependent plasticity are largely unknown. We performed repeated calcium imaging at neuronal resolution to track the tuning properties of populations of excitatory layer 2/3 neurons in mouse visual cortex during or after the critical period, as well as in mutant mice that sustain critical-period plasticity as adults. The instability of tuning for populations of neurons was greater in juvenile mice and adult mutant mice.
View Article and Find Full Text PDFEncorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Nat Med
January 2025
Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), University of Vic - Central University of Catalonia, Barcelona, Spain.
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC.
View Article and Find Full Text PDFA novel quantitative trait locus for barley yellow dwarf virus resistance and kernel traits on chromosome 2D of a wheat cultivar Jagger.
Plant Genome
March 2025
Department of Agronomy, Kansas State University, Manhattan, Kansas, USA.
Barley yellow dwarf (BYD) is one of the most serious viral diseases in cereal crops worldwide. Identification of quantitative trait loci (QTLs) underlining wheat resistance to barley yellow dwarf virus (BYDV) is essential for breeding BYDV-tolerant wheat cultivars. In this study, a recombinant inbred line (RIL) population was developed from the cross between Jagger (PI 593688) and a Jagger mutant (JagMut1095).
View Article and Find Full Text PDFApWD40a, a Member of the WD40-Repeat Protein Family, Is Crucial for Fungal Development, Toxin Synthesis, and Pathogenicity in the Ginseng Alternaria Leaf Blight Fungus .
J Fungi (Basel)
January 2025
College of Plant Protection, Jilin Agricultural University, Changchun 130118, China.
, the primary pathogen that causes ginseng Alternaria leaf blight disease, can lead to a 20-30% reduction in ginseng yield. WD40 repeat-containing proteins are evolutionarily conserved proteins with diverse functions between different organisms. In this study, we characterized the roles of a WD40 repeat-containing protein in .
View Article and Find Full Text PDFProtease-activated receptor 1 in the pathogenesis of cystic fibrosis.
BMJ Open Respir Res
January 2025
Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Background: The most common cause of death in those with cystic fibrosis (CF) is respiratory failure due to bronchiectasis resulting from repeated cycles of respiratory infection and inflammation. Protease-activated receptor 1 (PAR1) is a cell surface receptor activated by serine proteases including neutrophil elastase, which is recognised as a potent modulator of inflammation. While PAR1 is known to play an important role in regulating inflammation, nothing is known about any potential role of this receptor in CF pathogenesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!